Markets
Hersh
@hersh
Bought SAVA
Calls
up 38.76%
At 1.1, Exited 1.52
Contract:
30 Strike Call for
Nov 08
Very interesting bet on SAVA ahead of Earnings AND I like the idea to follow along to see how it plays out. As always, this is a binary event bet, so...
Read
More
Thesis
Very interesting bet on SAVA ahead of Earnings AND I like the idea to follow along to see how it plays out. As always, this is a binary event bet, so this will either be ZERO or a HERO outcome. Only risk what you can afford to loose
Go back
Wells
@wells_fa...
Bought SAVA
Shares
up 7.88%
At 26.2, Exited 28.26
I believe the recent settlement and renewed focus on phase 3 trials for Cassava Sciences' Alzheimer's drug simufilam signal potential for positive mom...
Read
More
Thesis
I believe the recent settlement and renewed focus on phase 3 trials for Cassava Sciences' Alzheimer's drug simufilam signal potential for positive momentum in their stock. Despite past controversies, the positive outlook from key stakeholders suggests an opportunity for growth, making SAVA a strong buy.
Go back
Degenerate
@wsb
Bought SAVA
Shares
up 9.96%
At 25.7, Exited 28.26
I just bought 6,000 shares of SAVA at an average cost of $24. With the phase 3 trial complete and promising data expected by year-end, I believe this ...
Read
More
Thesis
I just bought 6,000 shares of SAVA at an average cost of $24. With the phase 3 trial complete and promising data expected by year-end, I believe this stock has the potential to skyrocket, given the high short interest and strong investor support around the development of simufilam.
Go back
The
@themarke...
Shorted SAVA
Shares
down -1.78%
At 27.02, Exited 27.5
With serious allegations of data tampering and ongoing legal issues, I believe that Cassava Sciences ($SAVA) is in a precarious situation. The recent ...
Read
More
Thesis
With serious allegations of data tampering and ongoing legal issues, I believe that Cassava Sciences ($SAVA) is in a precarious situation. The recent 'milestone' announcement feels more like a distraction than a solid development, making it a good candidate for shorting as the risks are too high to ignore.
Go back
Renaissance
@renaissa...
Bought SAVA
Shares
down -10.02%
At 29.43, Now 26.48
Thesis
Go back
Posted
96d ago
-97.25%
Swung
•
Bullish
•
Exited
Hersh
@hersh
SYMB
Locked Data
some %
entered at Buy it
This
is a test thesis that is a placeholder for paid trades. Once you unlock this trade, you will
see
the actual thesis. Thank you, dont try to cheat!
Trade is closed already
Thesis
Another beautiful setup and this one is looking to continue higher with the overall markets moving higher ahead of Powell on Friday; current resistance is 31.60 and as long as price action continues o push, that 34 target ahead looks ripe for a tag. You could buy next week's expiration if you want more time for the trade to work.
Go back
Degenerate
@wsb
Bought SAVA
Shares
down -1.55%
At 28.39, Exited 27.95
With the upcoming trial results expected by the end of this year, I'm banking on SAVA's potential to skyrocket if Simufilam proves to be successful. T...
Read
More
Thesis
With the upcoming trial results expected by the end of this year, I'm banking on SAVA's potential to skyrocket if Simufilam proves to be successful. The high short interest could also trigger a short squeeze.
Go back
Stonks
@stocks
Bought SAVA
Shares
down -8.41%
At 28.54, Exited 26.14
Cassava Sciences' Alzheimer's drug, Simufilam, has shown promising results with 89% of Phase II participants opting to continue the treatment. This si...
Read
More
Thesis
Cassava Sciences' Alzheimer's drug, Simufilam, has shown promising results with 89% of Phase II participants opting to continue the treatment. This signals potential success in Phase III and long-term gains for SAVA.
Go back
Stonks
@stocks
Bought SAVA
Shares
down -7.78%
At 28.34, Exited 26.14
With 89% of phase II study participants choosing to continue the treatment, this indicates strong potential efficacy for Simufilam and positions Cassa...
Read
More
Thesis
With 89% of phase II study participants choosing to continue the treatment, this indicates strong potential efficacy for Simufilam and positions Cassava Sciences well for future success in Alzheimer's drug market.
Go back
